Estimation of induction and maintenance costs of infliximab, adalimumab and certolizumab pegol in managing Crohn's disease

被引：0
|
作者：
Feagan, Brian
Tan, Seng
Malone, Daniel
Hinojosa, Joaquin
Brown, Martin
机构：
[1] Robarts Res Inst, London, ON N6A 5C1, Canada
[2] UCB, Global Hlth Outcomes Res, Slough, Berks, England
[3] Univ Arizona, Coll Pharm, Tucson, AZ 85721 USA
[4] Hosp Sagunto, Gastroenterol Unit, Valencia, Spain
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2008年 / 103卷
关键词：
D O I：
10.14309/00000434-200809001-00999
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
999
引用
收藏
页码：S392 / S392
页数：1
相关论文
共 50 条
  • [1] Estimation of induction and maintenance costs of Infliximab, Adalimumab and Certolizumab Pegol in managing Crohn's Disease
    Feagan, B.
    Tan, S.
    Malone, D.
    Hinojosa, J.
    Brown, M.
    INFLAMMATORY BOWEL DISEASES, 2008, 14 (12) : S33 - S33
  • [2] CERTOLIZUMAB PEGOL IN CROHN'S DISEASE REFRACTORY TO INFLIXIMAB AND ADALIMUMAB
    Jose, Morales Lara Ma
    Penella Monica, Martinez
    Guzman Diana, Lacruz
    Vidal Vanessa, Jorge
    Maneiro Vicente, Santaclara
    Sanchez Senador, Moran
    del Carmen, Mira Sirvent Ma
    ATENCION FARMACEUTICA, 2009, 11 (03): : 178 - 180
  • [3] Clinical Response to Infliximab after Secondary Failure with Adalimumab or Certolizumab Pegol in Crohn's Disease
    Trivella, Juan
    Yarur, Andres
    Moroney, James
    Deshpande, Amar
    Abreu, Maria
    Sussman, Daniel
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2013, 108 : S560 - S561
  • [4] Maintenance therapy with certolizumab pegol for Crohn's disease
    Schreiber, Stefan
    Khaliq-Kareemi, Mani
    Lawrance, Ian C.
    Thomsen, Ole Ostergaard
    Hanauer, Stephen B.
    McColm, Juliet
    Bloomfield, Ralph
    Sandborn, William J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (03): : 239 - 250
  • [5] Pharmakokinetics of Certolizumab Pegol Induction in Crohn's Disease
    Wolf, Douglas C.
    Wolf, Christine
    GASTROENTEROLOGY, 2015, 148 (04) : S867 - S868
  • [6] Certolizumab pegol for induction of remission in Crohn's disease
    Yamazaki, Hajime
    So, Ryuhei
    Matsuoka, Katsuyoshi
    Kobayashi, Taku
    Shinzaki, Shinichiro
    Matsuura, Minoru
    Okabayashi, Shinji
    Kataoka, Yuki
    Tsujimoto, Yasushi
    Furukawa, Toshi A.
    Watanabe, Norio
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2019, (08):
  • [7] Risk-benefit Assessment of Adalimumab and Certolizumab Pegol as Induction Treatment for Crohn's Disease
    Colombel, Jean-Frederic
    Panaccione, R.
    Robinson, Anne
    Thakkar, Roopal
    Huang, Bidan
    Pollack, Paul
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2011, 106 : S466 - S466
  • [8] Antibodies to certolizumab pegol in patients with Crohn's disease do not cross-react with adalimumab, etanercept, or infliximab
    Vetterlein, Olivia M.
    Nesbitt, Andrew M.
    Stephens, Sue
    GASTROENTEROLOGY, 2007, 132 (04) : A556 - A556
  • [9] Crohn's disease - infliximab, adalimumab and certolizumab-pegol: clinical value of anti-TNF-α treatment
    Schreiber, S.
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2007, 132 (34-35) : 1770 - 1774
  • [10] HEALTHCARE SERVICE UTILIZATION AND COSTS OF CERTOLIZUMAB PEGOL VERSUS INFLIXIMAB TREATMENT IN PATIENTS WITH CROHN'S DISEASE
    Tkacz, Joseph
    Lee, Edward
    Low, Robert
    Stark, Jeffrey
    Yassine, Mohamed
    Brady, Brenna L.
    INFLAMMATORY BOWEL DISEASES, 2018, 24 : S15 - S15
12345